Neuphoria Therapeutics Inc..
NEUP.US | Research and experimental development on natural sciences and engineering
Neuphoria Therapeutics Inc. is a biotechnology company focused on the discovery, development, and commercialization of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company's research and development efforts are centered on identifying and developing innova...Show More
Better Health for All
30
Neuphoria Therapeutics Inc. is entirely focused on developing novel therapeutics for neurological and neuropsychiatric disorders, including social anxiety disorder (SAD), post-traumatic stress disorder (PTSD), and Alzheimer's disease.
1
Its lead drug candidate, BNC210, is designed to have rapid anti-anxiety effects without sedation, cognitive impairment, or addiction potential, and is described as well-tolerated.
2
The company is actively engaged in clinical trials, including a Phase 3 trial for BNC210 in SAD, with topline results anticipated in Q3 2025, and a Phase 2 trial for MK-1167 in Alzheimer's disease.
3
Neuphoria has held successful End-of-Phase 2 meetings with the FDA for BNC210 in both SAD and PTSD, reaching agreement on the design of its registrational program.
4
The company's core focus on anxiety disorders and PTSD demonstrates a strong commitment to mental health initiatives. The company conducts clinical trials, and while specific ethical details are not provided, the successful FDA meetings imply adherence to regulatory standards.
Fair Money & Economic Opportunity
0
No evidence available to assess Neuphoria Therapeutics Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Neuphoria Therapeutics Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles regarding Neuphoria Therapeutics Inc.'s performance on fair trade certifications, supply chain audit frequency, forced or child labor incidents, traceability coverage, remediation speed for ethical sourcing violations, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend. Therefore, no KPIs can be scored against the 'Fair Trade & Ethical Sourcing' value.
Honest & Fair Business
0
No specific, concrete data points were found in the provided articles to assess Neuphoria Therapeutics Inc. against any of the KPIs for the 'Honest & Fair Business' value. The articles primarily focus on clinical trial updates.
1
Some articles were inaccessible due to throttling.
2
The articles do not contain information regarding regulatory fines, transparency benchmarks, whistleblower policies, financial restatements, audit coverage, ESG controversies, complaint resolution times, board independence, anti-corruption policies, or third-party verification of ethical claims.
3
Kind to Animals
0
The provided articles discuss general FDA policies and regulatory changes regarding animal testing in drug development, including the FDA Modernization Act 2.0 and the encouragement of New Approach Methodologies (NAMs).
1
However, they do not contain any specific data, policies, or actions directly attributable to Neuphoria Therapeutics Inc. (NEUP.US) concerning its animal welfare practices, alternative testing methods, or any other relevant KPIs.
No War, No Weapons
0
No evidence available to assess Neuphoria Therapeutics Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Neuphoria Therapeutics Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No evidence available to assess Neuphoria Therapeutics Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Neuphoria Therapeutics Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence was found in the provided articles regarding Neuphoria Therapeutics Inc.'s performance on waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1
The articles primarily discuss corporate re-domiciliation and drug development efforts.